5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-(2-chlorophenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine | 544671-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-(2-chlorophenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine
• 英文别名: 5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-chloro-7-(2-chlorophenyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
• CAS: 544671-96-7
• 化学式: C₂₄H₁₆Cl₂F₆N₂O₂
• 分子量: 549.3
• InChiKey: UEINTTZEVVYGHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-吡咯烷-1-基哌啶 、 5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-(2-chlorophenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine 以to obtain 5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-chlorophenyl)-6-oxo-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine (57.7 mg, 48%)的产率得到5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-chlorophenyl)-6-oxo-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine
  参考文献：
  名称：

  Fused bicyclic pyridine derivatives as tachykinin receptor antagonists

  摘要：

  下列一种新型的融合双环吡啶衍生物或其盐，作为一种速激肽受体拮抗剂，特别是NK1受体拮抗剂，其通式如下（1）：其中，环A和环B分别为苯环，可以有1-3个取代基（任意相邻两个可以结合形成环）；环C为含氮环，氢原子被氮原子取代；R1和R2分别为氢原子、C1-C6烷基、C1-C6烷基磺酰基、C1-C6烷基羰基或C1-C6烷氧羰基，或R1和R2结合形成环D；m为1或2；n为2或3；q为1-4的整数。

  公开号：

  US20050107375A1
• 作为产物：
  描述：

  5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-chlorophenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine 在 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-(2-chlorophenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine
  参考文献：
  名称：

  Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 antagonists

  摘要：

  Novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones were designed and prepared as part of a search for NK1 antagonists. Structure-activity relationship studies indicated that the conformational restriction resulting from the incorporation of an oxazocine ring and the presence of a terminal heteroatom on the cyclic amino group at the C-9 position play important roles in NK1, receptor recognition. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.091

文献信息

• Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
  申请人：Seto Shigeki

  公开号：US20050107375A1

  公开（公告）日：2005-05-19

  A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1): wherein the rings A and B are each a benzene ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom; R 1 and R 2 are each independently a hydrogen atom, a C 1 to C 6 alkyl group, a C 1 to C 6 alkylsulfonyl group, a C 1 to C 6 alkylcarbonyl group, or a C 1 to C 6 alkoxycarbonyl group, or R 1 and R 2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.

  下列一种新型的融合双环吡啶衍生物或其盐，作为一种速激肽受体拮抗剂，特别是NK1受体拮抗剂，其通式如下（1）：其中，环A和环B分别为苯环，可以有1-3个取代基（任意相邻两个可以结合形成环）；环C为含氮环，氢原子被氮原子取代；R1和R2分别为氢原子、C1-C6烷基、C1-C6烷基磺酰基、C1-C6烷基羰基或C1-C6烷氧羰基，或R1和R2结合形成环D；m为1或2；n为2或3；q为1-4的整数。
• FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP1457493A1

  公开（公告）日：2004-09-15

  A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1):    wherein the rings A and B are each a benzene'ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring);    the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom;    R1 and R2 are each independently a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkoxycarbonyl group, or R1 and R2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.

  一种可作为速激肽受体拮抗剂，特别是 NK1 受体拮抗剂的新型融合双环吡啶衍生物或其盐由下式（1）表示： 其中环 A 和环 B 各为苯环，可有 1 至 3 个取代基（其中任意相邻的两个可相互结合形成环）； 环 C 是含氮环，其中有一个被氮原子取代的氢原子； R1和R2各自独立地为氢原子、C1至C6烷基、C1至C6烷磺酰基、C1至C6烷羰基或C1至C6烷氧羰基，或R1和R2彼此结合形成环D；m为1或2；n为2或3；q为1至4的整数。
• US7030107B2
  申请人：——

  公开号：US7030107B2

  公开（公告）日：2006-04-18
• Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 antagonists
  作者：Shigeki Seto、Asao Tanioka、Makoto Ikeda、Shigeru Izawa

  DOI：10.1016/j.bmcl.2004.12.091

  日期：2005.3

  Novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones were designed and prepared as part of a search for NK1 antagonists. Structure-activity relationship studies indicated that the conformational restriction resulting from the incorporation of an oxazocine ring and the presence of a terminal heteroatom on the cyclic amino group at the C-9 position play important roles in NK1, receptor recognition. (c) 2005 Elsevier Ltd. All rights reserved.